BiotechTube
Route 92 Medical

Route 92 Medical

San Mateo, United States· Est.
route92medical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $133M

Overview

Route 92 Medical is a neurovascular medical device innovator tackling key limitations in endovascular stroke therapy, such as difficult vessel access and procedural inefficiency. Its flagship technology platform, centered on the Tenzing delivery catheter and FreeClimb reperfusion systems, is designed to navigate tortuous anatomy more reliably and enable faster, more effective clot removal. The company is in the commercial stage for its initial products while also conducting a pivotal trial (SUMMIT MAX) for its next-generation HiPoint Reperfusion System, positioning it in the high-growth stroke intervention market.

Acute Ischemic StrokeNeurovascular Disease

Technology Platform

Integrated neurovascular access and intervention platform featuring the Tenzing delivery catheter (designed to navigate tortuous anatomy and deliver devices to the clot face without crossing) and the FreeClimb aspiration catheter systems. The platform aims to streamline mechanical thrombectomy procedures.

Funding History

3
Total raised:$133M
Series C$73M
Series B$40M
Series A$20M

Opportunities

The large and growing global market for stroke thrombectomy devices presents a major opportunity, especially as treatment guidelines expand to more patients.
Route 92's technology addresses specific inefficiencies in current procedures (time, access failure), which could drive rapid adoption if supported by strong clinical data.
A successful outcome from the SUMMIT MAX trial for the HiPoint system could position the company as a leader in next-generation stroke intervention.

Risk Factors

The company faces significant clinical and regulatory risk, as the success of its key HiPoint platform depends on the ongoing SUMMIT MAX trial.
It also operates in a highly competitive market dominated by large, established medical device companies with greater resources.
As a private company, it carries financial risk related to capital availability and the cost of commercializing products and running pivotal trials.

Competitive Landscape

Route 92 Medical competes in the neurothrombectomy market against large, well-established players like Medtronic, Stryker, Johnson & Johnson, and Penumbra. These competitors have broad portfolios, extensive clinical data, and significant sales and marketing resources. Route 92's differentiation is its focused platform designed specifically for rapid, reliable access in tortuous anatomy, aiming to compete on procedural efficiency rather than a full portfolio.

More companies in Digital Health & Biotech SaaS →More companies in United States →